UOC
MLYS icon

UBS O'Connor’s Mineralys Therapeutics MLYS Stock Holding History

UBS O'Connor’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,723
Closed -$1.08M – 386
2025
Q2 		$1.08M Buy
79,723
+6,375
+9% +$92.4K 0.03% 205
2025
Q1 		$1.16M Buy
73,348
+45,280
+161% +$521K 0.03% 173
2024
Q4 		$346K Sell
28,068
-3,000
-10% -$39.2K 0.01% 305
2024
Q3 		$376K Sell
31,068
-28,863
-48% -$349K 0.01% 361
2024
Q2 		$701K Buy
59,931
+1,457
+2% +$18.4K 0.02% 342
2024
Q1 		$755K Sell
58,474
-127,694
-69% -$1.58M 0.02% 303
2023
Q4 		$1.6M Buy
+186,168
New +$1.46M 0.05% 210

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return